Dr. Reddys Laboratories Ltd.

Dr. Reddy's Laboratories has launched Penicillamine Capsules USP, 250 mg, a therapeutic equivalent generic version of Cuprimine (penicillamine) Capsules, 250 mg, approved by the U.S. Food and Drug Administration (USFDA).

The Cuprimine brand and generic market had U.S. sales of approximately $80 million MAT for the most recent twelve months ending in June 2020 according to IQVIA Health. The company’s Penicillamine Capsules, USP is available as 250 mg capsules in a bottle count sizes of 100.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.